BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 33676540)

  • 1. M2 macrophage-derived exosomal microRNAs inhibit cell migration and invasion in gliomas through PI3K/AKT/mTOR signaling pathway.
    Yao J; Wang Z; Cheng Y; Ma C; Zhong Y; Xiao Y; Gao X; Li Z
    J Transl Med; 2021 Mar; 19(1):99. PubMed ID: 33676540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-derived exosomes deliver the tumor suppressor miR-3591-3p to induce M2 macrophage polarization and promote glioma progression.
    Li M; Xu H; Qi Y; Pan Z; Li B; Gao Z; Zhao R; Xue H; Li G
    Oncogene; 2022 Oct; 41(41):4618-4632. PubMed ID: 36085418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiRNA-92a promotes cell proliferation and invasion through binding to KLF4 in glioma.
    Liu PJ; Ye YX; Wang YX; Du JX; Pan YH; Fang XB
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(15):6612-6620. PubMed ID: 31378903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Swainsonine represses glioma cell proliferation, migration and invasion by reduction of miR-92a expression.
    Sun L; Jin X; Xie L; Xu G; Cui Y; Chen Z
    BMC Cancer; 2019 Mar; 19(1):247. PubMed ID: 30890138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum exosome-derived miR-146a-3p promotes macrophage M2 polarization in allergic rhinitis by targeting VAV3 via PI3K/AKT/mTOR pathway.
    Xia C; Zhu K; Zhang Y; Chen J; Yu C; Gao T; Zheng G
    Int Immunopharmacol; 2023 Nov; 124(Pt B):110997. PubMed ID: 37783052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exosomal DLX6-AS1 from hepatocellular carcinoma cells induces M2 macrophage polarization to promote migration and invasion in hepatocellular carcinoma through microRNA-15a-5p/CXCL17 axis.
    Wang LP; Lin J; Ma XQ; Xu DY; Shi CF; Wang W; Jiang XJ
    J Exp Clin Cancer Res; 2021 May; 40(1):177. PubMed ID: 34039401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MicroRNA-32 targeting PTEN enhances M2 macrophage polarization in the glioma microenvironment and further promotes the progression of glioma.
    Bao L; Li X
    Mol Cell Biochem; 2019 Oct; 460(1-2):67-79. PubMed ID: 31218569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exosomal microRNA-15a from ACHN cells aggravates clear cell renal cell carcinoma via the BTG2/PI3K/AKT axis.
    Li DY; Lin FF; Li GP; Zeng FC
    Kaohsiung J Med Sci; 2021 Nov; 37(11):973-982. PubMed ID: 34337864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective effect of hsa-miR-570-3p targeting CD274 on triple negative breast cancer by blocking PI3K/AKT/mTOR signaling pathway.
    Wang LL; Huang WW; Huang J; Huang RF; Li NN; Hong Y; Chen ML; Wu F; Liu J
    Kaohsiung J Med Sci; 2020 Aug; 36(8):581-591. PubMed ID: 32311203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-210 promotes hepatocellular carcinoma progression by modulating macrophage autophagy through PI3K/AKT/mTOR signaling.
    Bi S; Zhang Y; Zhou J; Yao Y; Wang J; Fang M; Li B; Wu C; Ren C
    Biochem Biophys Res Commun; 2023 Jun; 662():47-57. PubMed ID: 37099810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiRNAs Mediate GDNF-Induced Proliferation and Migration of Glioma Cells.
    Zhang BL; Dong FL; Guo TW; Gu XH; Huang LY; Gao DS
    Cell Physiol Biochem; 2017; 44(5):1923-1938. PubMed ID: 29224008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor-derived exosomal miR-148b-3p mediates M2 macrophage polarization via TSC2/mTORC1 to promote breast cancer migration and invasion.
    Hao C; Sheng Z; Wang W; Feng R; Zheng Y; Xiao Q; Zhang B
    Thorac Cancer; 2023 Jun; 14(16):1477-1491. PubMed ID: 37144254
    [TBL] [Abstract][Full Text] [Related]  

  • 13. hUC-MSCs exosomal miR-451 alleviated acute lung injury by modulating macrophage M2 polarization via regulating MIF-PI3K-AKT signaling pathway.
    Liu J; Xing F; Fu Q; He B; Jia Z; Du J; Li Y; Zhang X; Chen X
    Environ Toxicol; 2022 Dec; 37(12):2819-2831. PubMed ID: 35997581
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MiR-92a-3p Promotes the Malignant Progression of Hepatocellular Carcinoma by Mediating the PI3K/AKT/mTOR Signaling Pathway.
    Wang L; Cui M; Qu F; Cheng D; Yu J; Tang Z; Cheng L; Wei Y; Wu X; Liu X
    Curr Pharm Des; 2021; 27(29):3244-3250. PubMed ID: 34126886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA-99b suppresses human cervical cancer cell activity by inhibiting the PI3K/AKT/mTOR signaling pathway.
    Li YJ; Wang Y; Wang YY
    J Cell Physiol; 2019 Jun; 234(6):9577-9591. PubMed ID: 30480801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Downregulation of lncRNA ZEB1-AS1 Represses Cell Proliferation, Migration, and Invasion Through Mediating PI3K/AKT/mTOR Signaling by miR-342-3p/CUL4B Axis in Prostate Cancer.
    Ma T; Chen H; Wang P; Yang N; Bao J
    Cancer Biother Radiopharm; 2020 Nov; 35(9):661-672. PubMed ID: 32275162
    [No Abstract]   [Full Text] [Related]  

  • 17. OxLDL-stimulated macrophage exosomes promote proatherogenic vascular smooth muscle cell viability and invasion via delivering miR-186-5p then inactivating SHIP2 mediated PI3K/AKT/mTOR pathway.
    Ren L; Chen S; Yao D; Yan H
    Mol Immunol; 2022 Jun; 146():27-37. PubMed ID: 35421738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Macrophages derived exosomes deliver miR-223 to epithelial ovarian cancer cells to elicit a chemoresistant phenotype.
    Zhu X; Shen H; Yin X; Yang M; Wei H; Chen Q; Feng F; Liu Y; Xu W; Li Y
    J Exp Clin Cancer Res; 2019 Feb; 38(1):81. PubMed ID: 30770776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MiR-155-5p exerts tumor-suppressing functions in Wilms tumor by targeting IGF2 via the PI3K signaling pathway.
    Luo X; Dong J; He X; Shen L; Long C; Liu F; Liu X; Lin T; He D; Wei G
    Biomed Pharmacother; 2020 May; 125():109880. PubMed ID: 32004974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic cancer stem cell-derived exosomal miR-210 mediates macrophage M2 polarization and promotes gemcitabine resistance by targeting FGFRL1.
    Guo Y; Cui J; Liang X; Chen T; Lu C; Peng T
    Int Immunopharmacol; 2024 Jan; 127():111407. PubMed ID: 38134594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.